Title | Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data |
Authors | Kong, Xiangyi Qi, Yihang Huang, Junjie Zhao, Yang Zhan, Yongle Qin, Xuzhen Qi, Zhihong Atanda, Adejare (Jay) Zhang, Lei Wang, Jing Fang, Yi Jia, Peng Golozar, Asieh Zhang, Lin Jiang, Yu |
Affiliation | Chinese Acad Med Sci, Natl Canc Ctr, Dept Breast Surg Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China Peking Union Med Coll, Beijing 100021, Peoples R China Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China Peking Univ, George Inst Global Hlth, Hlth Sci Ctr, Beijing, Peoples R China Univ Melbourne, WHO Collaborating Ctr Implementat Res Prevent & C, Melbourne, Vic 3010, Australia Chinese Acad Med Sci, Sch Populat Med & Publ Hlth, Beijing 100021, Peoples R China Chinese Acad Med Sci, Peking Union Med Coll Hosp, Clin Lab, Beijing 100730, Peoples R China Peking Union Med Coll, Beijing 100730, Peoples R China Morgan State Univ, Sch Community Hlth & Policy, Baltimore, MD 21239 USA Xi An Jiao Tong Univ, China Australia Joint Res Ctr Infect Dis, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shanxi, Peoples R China Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia Zhengzhou Univ, Coll Publ Hlth, Dept Epidemiol & Biostat, Zhengzhou 450001, Henan, Peoples R China Hong Kong Polytech Univ, Dept Land Surveying & Geoinformat, Hong Kong, Peoples R China Int Inst Spatial Lifecourse Epidemiol ISLE, Hong Kong, Peoples R China Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA Regeneron Pharmaceut, New York, NY USA Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia Victorian Comprehens Canc Ctr, Ctr Canc Res, Melbourne, Vic, Australia |
Keywords | CORONAVIRUS DISEASE 2019 MORTALITY OUTCOMES CHINA COMORBIDITIES MULTICENTER MANAGEMENT PNEUMONIA WUHAN RISK |
Issue Date | 28-Jun-2021 |
Publisher | CANCER LETTERS |
Abstract | There are minimal data regarding the prevalence of cancer in patients with coronavirus disease 2019 (COVID-19), as well as the incidence of severe illness and rate of mortality in COVID-19 patients with cancer. PubMed, Embase, Cochrane Library, and Web of Science were systematically searched, from database inception to July 15, 2020, for studies of patients with COVID-19 that included information regarding comorbid cancer. In total, 109 eligible global studies were included in this systematic review. Ninety studies with 94,845 COVID-19 patients, among which 4106 exhibited comorbid cancer, were included in the meta-analysis regarding prevalence of comorbid cancer. Twenty-three studies with 71,969 COVID-19 patients, among which 4351 with comorbid cancer had severe illness or death, were included in the meta-analysis. The overall prevalence of cancer among COVID-19 patients was 0.07 (95% CI 0.05-0.09). The cancer prevalence in COVID-19 patients was higher in Europe (0.22, 95% CI 0.17-0.28) than in the Asia-Pacific region (0.04, 95% CI 0.03-0.06) or North America (0.05, 95% CI 0.04-0.06). The cancer prevalence in COVID-19 patients aged >60 years was 0.10 (95% CI 0.07-0.14), while the prevalence among patients aged <= 60 years was 0.05 (95% CI 0.03-0.06). The pooled prevalence of severe illness among COVID-19 patients with cancer was 0.34 (95% CI 0.26-0.42) and the pooled mortality rate of COVID-19 patients with cancer was 0.20 (95% CI 0.16-0.25). Pooled incidences of severe illness among COVID-19 patients with cancer from Asia Pacific, Europe, and North America were 0.38 (95% CI 0.24-0.52), 0.39 (95% CI 0.25-0.53), and 0.26 (95% CI 0.20-0.31), respectively; pooled mortality rates from the Asia-Pacific region, Europe, and North America were 0.17 (95% CI 0.10-0.24), 0.26 (95% CI 0.18-0.35), and 0.19 (95% CI 0.13-0.25), respectively. |
URI | http://hdl.handle.net/20.500.11897/613004 |
ISSN | 0304-3835 |
DOI | 10.1016/j.canlet.2021.02.012 |
Indexed | SCI(E) |
Appears in Collections: | 医学部待认领 |